ARTICLE | Clinical News

Iniparib: Final Phase II data

October 18, 2010 7:00 AM UTC

Final data from a Phase II trial in 123 patients showed that BS1-201 plus Gemzar gemcitabine and carboplatin significantly improved median OS vs. Gemzar and carboplatin alone (12.3 vs. 7.7 months, HR=0.57). Median PFS for BS1-201 was 5.9 months vs. 3.6 months for chemotherapy alone (HR=0.59). Additionally, BSI-201 produced a CBR of 55.7% vs. 33.9% for chemotherapy alone. Data were presented at the European Society for Medical Oncology meeting in Milan. ...